Jon K. Bowden-Verhoek

NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation

Agata Habas, D. Bonhaus, D. Price, 2022, International journal of inflammation.

Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens.

L. Silvian, T. Bohnert, D. Erlanson, 2019, Bioorganic & medicinal chemistry.

Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse model.

George H Vandeveer, N. Powell, L. Silvian, 2022, Bioorganic & medicinal chemistry letters.

Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.

Y. Liu, L. Silvian, T. Bohnert, 2021, Bioorganic & medicinal chemistry.

NPT520-34 improves neuropathology and motor deficits in a transgenic mouse model of Parkinson's disease.

E. Masliah, W. Wrasidlo, D. Bonhaus, 2021, Brain : a journal of neurology.